tiprankstipranks
Advertisement
Advertisement

IONS Stock Latest News

Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome
Company AnnouncementsIonis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome
9h ago
8K
IONS
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
PremiumThe Fly
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
10h ago
NVS
IONS
Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside
PremiumRatings
Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside
10h ago
IONS
Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital
PremiumThe Fly
Ionis Pharmaceuticals price target raised to $61 from $60 at BMO Capital
19h ago
IONS
Ionis Pharmaceuticals: Buy Rating Reiterated as Early Zanvastro Approval, Rare-Disease Portfolio Strength, and Valuation Support Back Unchanged $115 Price Target
PremiumRatings
Ionis Pharmaceuticals: Buy Rating Reiterated as Early Zanvastro Approval, Rare-Disease Portfolio Strength, and Valuation Support Back Unchanged $115 Price Target
20h ago
IONS
Ionis wins FDA approval for ZANVASTRO in Alexander disease
PremiumCompany AnnouncementsIonis wins FDA approval for ZANVASTRO in Alexander disease
20h ago
8K
IONS
FDA approves Ionis drug to treat Alexander disease
Premium
The Fly
FDA approves Ionis drug to treat Alexander disease
1d ago
IONS
Ultragenyx downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Ultragenyx downgraded to Sector Perform from Outperform at RBC Capital
2d ago
IONS
RARE
Ionis Pharmaceuticals: Solid Product Momentum but Balanced Risk-Reward; Hold Rating and $69 Price Target Reiterated
PremiumRatings
Ionis Pharmaceuticals: Solid Product Momentum but Balanced Risk-Reward; Hold Rating and $69 Price Target Reiterated
5d ago
IONS
Ionis: TRYNGOLZA’s Competitive Moat Supports Reiterated Buy Rating and Unchanged $115 Price Target
PremiumRatings
Ionis: TRYNGOLZA’s Competitive Moat Supports Reiterated Buy Rating and Unchanged $115 Price Target
5d ago
IONS
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
PremiumThe Fly
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
8d ago
AZN
ALNY
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
PremiumThe Fly
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
8d ago
AZN
ALNY
Oppenheimer biotech analysts hold an analyst/industry conference call
PremiumThe FlyOppenheimer biotech analysts hold an analyst/industry conference call
9d ago
AZN
IONS
Trump Trade: U.S. considering new semiconductor tariffs
Premium
The Fly
Trump Trade: U.S. considering new semiconductor tariffs
9d ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
Premium
The Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
10d ago
ALKS
ALNY
Ionis announces new data in sHTG to be presented at ESC Congress 2026
PremiumThe Fly
Ionis announces new data in sHTG to be presented at ESC Congress 2026
16d ago
IONS
BMO Capital starts Ionis at Market Perform pending better visibility
PremiumThe Fly
BMO Capital starts Ionis at Market Perform pending better visibility
17d ago
IONS
Ionis Pharmaceuticals initiated with a Market Perform at BMO Capital
PremiumThe Fly
Ionis Pharmaceuticals initiated with a Market Perform at BMO Capital
17d ago
IONS
Ionis Pharmaceuticals Earnings Call Highlights Pipeline And Growth
PremiumCompany Announcements
Ionis Pharmaceuticals Earnings Call Highlights Pipeline And Growth
24d ago
IONS
Ionis Pharmaceuticals price target raised to $76 from $72 at JPMorgan
PremiumThe FlyIonis Pharmaceuticals price target raised to $76 from $72 at JPMorgan
1M ago
IONS
McCormick, Wabtec, Ecolab, Ionis, Fastenal Insider Shock
Premium
Weekend Updates
McCormick, Wabtec, Ecolab, Ionis, Fastenal Insider Shock
1M ago
ECL
MKC
Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating
Premium
Ratings
Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating
1M ago
IONS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >